Life Biosciences Initiates Gene Therapy Trial to Rejuvenate Aging Cells in Glaucoma Patients
Life Biosciences, a company based in Boston, Massachusetts, has commenced a groundbreaking clinical trial aimed at rejuvenating aging cells to treat glaucoma, a condition that can lead to blindness. The trial involves a novel gene therapy approach that activates three specific genes to 'partially reprogram' old cells, allowing them to behave as if they were young again. This method is intended to regenerate neurons in the optic nerve, which connects the eye to the brain and is typically damaged in glaucoma patients. The trial's first participant has already been treated, marking a significant milestone in the field of regenerative medicine. The approach is based on previous research conducted at Harvard Medical School, which demonstrated neuron regeneration and vision restoration in mice with damaged optic nerves. 
